Clinical Trials Logo

Clinical Trial Summary

The overall objective of the study is to assess the potential effects of the long-acting GLP-1 analogue exenatide in preventing/slowing the progression of cognitive dysfunction and related biomarkers in dysglycemic/prediabetic patients with mild cognitive impairment (MCI).


Clinical Trial Description

Type 2 Diabetes Mellitus (T2DM) and Alzheimer's Disease (AD) are two of the most common diseases of aging.The presence of T2DM almost doubles the risk of developing AD and is associated with a faster rate of cognitive decline in those with mild cognitive impairment (MCI). Blood glucose levels are directly associated with accelerated cognitive decline also in subjects with impaired fasting glucose and in individuals without clinical DM. Impaired insulin signaling is critically involved in the natural history of both T2DM and AD and it may represent a common mechanistic link ("common soil") between dysglycemic/prediabetic states and AD development and progression. The overall objective of the study is to assess the potential effects of the long-acting GLP-1 analogue exenatide in preventing/slowing the progression of cognitive dysfunction and related biomarkers in dysglycemic/prediabetic patients with mild cognitive impairment (MCI). All eligible patients at V0 will undergo baseline assessments (V1) and will be allocated according to the procedure of randomization to one of the study arms. Follow-up (FU) visits for all subjects will be at 16 (V2) and at 32 weeks (V3) after randomization. Additionally, subjects on active treatment will be admitted weekly to the Outpatient Diabetes Unit of the AOUPR for GLP-1 subcutaneous injections and to check for possible side effects. Subjects in the control arm will be seen at the Center for Dementia (AOUPR) according to their usual schedule. Laboratory and diagnostic: At each study visits patients will undergo: - anthropometric and hemodynamic assessment: weight and height for Body Mass Index (BMI) calculation, waist circumference, ambulatory blood pressure, heart rate; - blood test collection of metabolic profile: blood collection for metabolic/hormonal profile: fasting plasma glucose, HbA1c, insulin, C-peptide, glucagon, active GLP-1, total gastric inhibitory polypeptide (GIP), total cholesterol, HDL-cholesterol, triglycerides, AST, ALT, pancreatic amylase, lipase, creatinine, eGFR. - cognitive function tests: ADAS-cog and the quality score of MMSE, Phonemic verbal fluency test; Semantic verbal fluency test; Geriatric Depression Scale (GDS) ; Clinical Dementia Rating Scale (CDR); Neuropsychiatric Inventory (NPI); Activities of Daily Living (ADL); Instrumental Activities of Daily Living (IADL). ADAS-cog was designed to measure the severity of the most important symptoms of Alzheimer's disease. It consists of 11 7 tasks measuring the disturbances of memory, language, praxis, attention and other cognitive abilities which are often referred to as the core symptoms of AD. - Functional Magnetic Resonance Imaging (MRI)(only at V1 and V3). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02847403
Study type Interventional
Source Azienda Ospedaliero-Universitaria di Parma
Contact
Status Active, not recruiting
Phase Phase 3
Start date February 2016
Completion date October 31, 2021

See also
  Status Clinical Trial Phase
Terminated NCT03670017 - Glucose Time-In-Range Development Evaluation N/A
Recruiting NCT03306810 - Recognition and Treatment of Dysglycemia. AGS - Acute Glucose Service N/A
Recruiting NCT06019910 - Snus and Home Blood Pressure N/A
Active, not recruiting NCT01605422 - Meta-analyses of the Effect of Dietary Pulses on Acute Postprandial Metabolic Control N/A
Completed NCT04107922 - Nutraceutical on Hyperglycemia Phase 3
Completed NCT04107987 - Berberine, Curcumin, Inositol, Banaba and Chromium Picolinate in Patients With Fasting Dysglycemia Phase 3
Recruiting NCT06348550 - Effect of the Association of Berberine Fitosoma® and Monacolin K MonaKoPure® on Glyco-metabolic Parameters in Dysglycemic and Dyslipidemic Patients. N/A
Recruiting NCT06050265 - Glucose Evaluation Through Continuous Glucose Monitors in Polycystic Ovary Syndrome N/A
Not yet recruiting NCT02960373 - Dried Fruit and Postprandial Glycemia Trial N/A
Completed NCT03299205 - Alcohol & Metabolic Comorbidities in PLWHA: Evidence Driven Interventions N/A
Active, not recruiting NCT05191160 - The Soy Treatment Evaluation for Metabolic Health (STEM) Trial N/A
Recruiting NCT05852054 - Supporting Transitions to Primary Care Among Under-resourced, Postpartum Women (STEP-UP) Phase 3
Active, not recruiting NCT04767672 - Study to Assess the Effects of Non Digestible Carbohydrates on Long-Term Glucose Homeostasis in Untreated Prediabetic Subjects N/A
Completed NCT03543644 - Strategies To OPpose Sugars With Non-nutritive Sweeteners Or Water (STOP Sugars NOW) Trial N/A
Recruiting NCT05277558 - Brain Health in Youth With Normal Weight, Overweight and Obesity at Risk for Type 2 Diabetes (T2D)
Completed NCT04525508 - Coronary Artery Plaque Burden in Asymptomatic Danish Men Aged 65-75 Years and the Relation to Glycemic Status.
Active, not recruiting NCT02037321 - Meta-Analyses of the Effect of Vegetable Protein for Animal Protein on Cardiometabolic Risk N/A
Active, not recruiting NCT01608620 - Meta-analyses of Fructose-containing Sugars and Incident Cardiometabolic Disease N/A
Active, not recruiting NCT01608607 - Meta-analysis of Fructose-Containing Sugar Sweetened Beverages (SSBs) and Weight Change N/A
Completed NCT01630980 - Meta-analyses of the Effect of Tree Nuts on Glycemic Control and Features of the Metabolic Syndrome N/A